In NMSC, IL-17- and IL-22-producing lymphocytes have been identified in peritumoral skin, and in vitro and in vivo pre-clinical studies have suggested that IL-17 can promote tumor progression [61,62,63]. This evidence concerns the gene IL17A and neoplasm.